Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The hepatic
cysteine dioxygenase
activity of rats was markedly decreased by the intraperitoneal administration of
glucagon
. The enzyme activity was also decreased by either dibutyryl cyclic AMP or theophylline. The prior administration of actinomycin D completely blocked the
glucagon
-mediated decrease of enzyme activity, while administrations of this inhibitor of protein synthesis after
glucagon
injection did not block the decrease of enzyme activity. A single administration of actinomycin D resulted in a slight increase of
cysteine dioxygenase
activity in the rat liver. On the other hand, the injection of cycloheximide resulted in a rapid decrease of the hepatic
cysteine dioxygenase
with a half-life of 2.5 h. The half-life of the enzyme in rat liver after
glucagon
administration was one hour. The administration of hydrocortisone or insulin had no effect on the
glucagon
-mediated decrease of
cysteine dioxygenase
of rat liver. The enzyme activity of alloxan diabetic rat liver was almost the same as that of the intact rat liver. The evidence obtained here suggests that enhancement of degradation or inactivation of
cysteine dioxygenase
is responsible for the
glucagon
-mediated decrease of the enzyme activity in rat liver.
...
PMID:Decrease of rat liver cysteine dioxygenase (cysteine oxidase) activity mediated by glucagon. 21 16
